Table 2.

Treatment Effect on Time to Symptomatic Hypotension or Syncope by Vulnerable Subgroups

	Vericiguat Rate (Events)*	Placebo Rate (Events)*	Unadjusted		Adjusted
			HR (95% CI)	P value	HR (95% CI)	P value
Symptomatic hypotension or syncope
Age ≤75 y	12.03 (222)	9.61 (179)	1.26 (1.03–1.53)	0.28	1.23 (1.01–1.51)	0.42
Age >75 y	13.35 (90)	12.99 (88)	1.03 (0.77–1.39)		1.06 (0.78–1.44)
SBP ≥110 mm Hg	10.08 (193)	9.13 (178)	1.11 (0.91–1.36)	0.36	1.11 (0.90–1.37)	0.33
SBP <110 mm Hg	19.66 (119)	15.05 (89)	1.30 (0.99–1.71)		1.32 (0.99–1.75)
No use of ARNI	11.61 (258)	9.55 (212)	1.22 (1.02–1.46)	0.48	1.23 (1.02–1.49)	0.24
Use of ARNI	18.09 (54)	17.23 (55)	1.05 (0.72–1.53)		0.95 (0.64–1.41)
Symptomatic hypotension
Age ≤75 y	8.88 (168)	6.84 (130)	1.30 (1.04–1.64)	0.08	1.27 (1.00–1.61)	0.20
Age >75 y	8.85 (61)	9.96 (68)	0.90 (0.64–1.27)		0.96 (0.67–1.37)
SBP ≥110 mm Hg	7.14 (140)	6.34 (126)	1.14 (0.89–1.44)	0.82	1.13 (0.88–1.45)	0.70
SBP <110 mm Hg	14.36 (89)	12.06 (72)	1.19 (0.87–1.62)		1.23 (0.89–1.69)
No use of ARNI	8.12 (185)	6.87 (155)	1.19 (0.96–1.47)	0.73	1.21 (0.97–1.51)	0.48
Use of ARNI	14.53 (44)	13.20 (43)	1.10 (0.72–1.67)		1.01 (0.65–1.57)
Syncope
Age ≤75 y	3.53 (69)	3.13 (61)	1.13 (0.80–1.60)	0.72	1.15 (0.81–1.63)	0.94
Age >75 y	4.50 (32)	3.55 (26)	1.27 (0.76–2.13)		1.18 (0.69–2.02)
SBP ≥110 mm Hg	3.30 (66)	3.08 (63)	1.08 (0.76–1.52)	0.41	1.09 (0.77–1.55)	0.52
SBP <110 mm Hg	5.26 (35)	3.78 (24)	1.40 (0.83–2.35)		1.35 (0.79–2.30)
No use of ARNI	3.77 (88)	3.00 (70)	1.26 (0.92–1.73)	0.25	1.29 (0.93–1.77)	0.10
Use of ARNI	3.91 (13)	4.93 (17)	0.79 (0.39–1.63)		0.65 (0.30–1.38)

ARNI indicates angiotensin receptor neprilysin inhibitors; HR, hazard ratio; and SBP, systolic blood pressure.

^*Number of events per 100 patient‐years of follow‐up.